Josh Schimmer

Stock Analyst at Cantor Fitzgerald

(4.23)
# 473
Out of 5,042 analysts
141
Total ratings
53.54%
Success rate
14.24%
Average return

Stocks Rated by Josh Schimmer

Nuvalent
Oct 15, 2025
Initiates: Overweight
Price Target: $135
Current: $93.39
Upside: +44.56%
Invivyd
Oct 6, 2025
Initiates: Overweight
Price Target: $10
Current: $2.23
Upside: +348.43%
Avidity Biosciences
Sep 22, 2025
Maintains: Outperform
Price Target: $70$65
Current: $49.15
Upside: +32.25%
CG Oncology
Sep 8, 2025
Reiterates: Overweight
Price Target: $75
Current: $43.67
Upside: +71.74%
Denali Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $15.96
Upside: -
Septerna
Sep 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $21.67
Upside: +15.37%
Cabaletta Bio
Sep 5, 2025
Reiterates: Overweight
Price Target: $15
Current: $2.47
Upside: +507.29%
Rocket Pharmaceuticals
Aug 8, 2025
Maintains: Overweight
Price Target: $10$8
Current: $3.85
Upside: +107.79%
BridgeBio Pharma
Jul 29, 2025
Reiterates: Overweight
Price Target: $95
Current: $54.26
Upside: +75.08%
Trevi Therapeutics
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $10.51
Upside: +137.87%
Downgrades: In-Line
Price Target: $11$6
Current: $6.28
Upside: -4.46%
Maintains: Outperform
Price Target: $260$280
Current: $202.00
Upside: +38.61%
Reiterates: Overweight
Price Target: $50
Current: $10.70
Upside: +367.29%
Maintains: Overweight
Price Target: $23$20
Current: $5.41
Upside: +269.69%
Reiterates: Overweight
Price Target: $215
Current: $186.13
Upside: +15.51%
Downgrades: In-Line
Price Target: $5
Current: $2.21
Upside: +126.24%
Reiterates: Overweight
Price Target: $200
Current: $24.90
Upside: +703.21%
Reiterates: Overweight
Price Target: $25
Current: $47.98
Upside: -47.89%
Reiterates: Overweight
Price Target: n/a
Current: $3.69
Upside: -
Reiterates: Overweight
Price Target: $30
Current: $9.11
Upside: +229.31%
Downgrades: Neutral
Price Target: n/a
Current: $11.34
Upside: -
Reiterates: Overweight
Price Target: n/a
Current: $1.50
Upside: -
Reiterates: Overweight
Price Target: $90
Current: $40.99
Upside: +119.57%
Reiterates: Overweight
Price Target: n/a
Current: $2.37
Upside: -
Reiterates: Overweight
Price Target: n/a
Current: $159.66
Upside: -
Reiterates: Overweight
Price Target: n/a
Current: $38.00
Upside: -
Reiterates: Overweight
Price Target: n/a
Current: $11.22
Upside: -
Reiterates: Overweight
Price Target: n/a
Current: $3.21
Upside: -
Reiterates: Overweight
Price Target: n/a
Current: $84.68
Upside: -
Maintains: Outperform
Price Target: $15
Current: $0.61
Upside: +2,359.02%
Reiterates: Overweight
Price Target: $65
Current: $40.76
Upside: +59.47%
Maintains: Overweight
Price Target: $50$60
Current: $70.02
Upside: -14.31%
Downgrades: In-Line
Price Target: $43$5
Current: $5.81
Upside: -13.94%
Maintains: Outperform
Price Target: $20$11
Current: $2.38
Upside: +362.18%
Downgrades: In-Line
Price Target: $140$130
Current: $144.00
Upside: -9.72%
Downgrades: In-Line
Price Target: $760
Current: $577.95
Upside: +31.50%
Initiates: Outperform
Price Target: $15
Current: $17.74
Upside: -15.45%
Initiates: Outperform
Price Target: $55
Current: $7.76
Upside: +608.76%
Initiates: Outperform
Price Target: $30
Current: $2.01
Upside: +1,392.54%
Downgrades: In-Line
Price Target: n/a
Current: $1.46
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $13.03
Upside: -
Upgrades: Outperform
Price Target: $222$250
Current: $421.50
Upside: -40.69%
Upgrades: Outperform
Price Target: n/a
Current: $91.28
Upside: -
Downgrades: In-Line
Price Target: n/a
Current: $70.86
Upside: -
Downgrades: In-Line
Price Target: n/a
Current: $4.65
Upside: -
Initiates: Outperform
Price Target: $22
Current: $61.01
Upside: -63.94%
Initiates: Outperform
Price Target: n/a
Current: $14.25
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $54.48
Upside: -
Initiates: Outperform
Price Target: $95
Current: $227.99
Upside: -58.33%